Measurable Residual Disease (MRD) Focus

Understanding Clinical Endpoints In Measurable Residual Disease

The MRD Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Adaptive Biotechnologies, and Pfizer. These supporters have no influence over the production of the content.

Welcome to Measurable Residual Disease (MRD) Focus.

Explore the cutting-edge updates in MRD by disease type, including expert interviews from major international congresses, podcasts and e-learning.

MRD is the term used to describe a small number of cancer cells remaining in patients following treatment, which are below the level of routine morphological detection1,2. Even when a patient is in remission it is possible for them to be ‘MRD positive’. The level of MRD can, theoretically, be used as a prognostic indicator to determine treatment efficacy and to detect cancer recurrence. MRD status is now increasingly measured as an endpoint in clinical trials for haematological malignancies, with the goal of treatment being MRD negativity.

  1. Ossenkoppele G, Schuurhuis GJ. MRD in AML: time for redefinition of CR? Blood. 2013 Mar 21; 121(12): 2166-2168.
  2. Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018 Jun 12; 2(11): 1356-1366.

Videos by Disease Area

Multiple Myeloma
CLL
Lymphoma
AML
ALL

Videos by Congress

SOHO 2022
IMS 2022
ISA 2022
EHA 2022
ASCO 2022
COMy 2022
TCT 2022
BSH 2022
EBMT 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter